Posted on 7/9/18
Biogen And Eisai Tease An Alzheimer's Result
OK, we have kind of a complicated situation today. Biogen (NASDAQ:BIIB) and Eisai (EASLF) (EASLY) have press-released what appear to be positive results for an anti-amyloid . . .
Posted on 7/9/18
Paratek Pharmaceuticals: Three PDUFA Dates, One Option Trade
Editor's note: Seeking Alpha is proud to welcome JV Biotech as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for . . .
Posted on 7/9/18
3 Biotech Stocks That Soared This Week: Are They Buys?
Gaining 22% in a year is a very good return for most stocks. But racking up that much or more in just a week is better . . .
Posted on 7/9/18
Why Biogen Inc. Stock Soared 15.2% Today
What happenedShares of Biogen Inc. (NASDAQ:BIIB) were up 15.2% as of 11:35 a.m. EDT on Friday after the biotech, along with partner Eisai, reported encouraging results . . .
Posted on 7/6/18
Melinta Therapeutics: Could The H.R. 6294 Bill Improve The Prospects Of Antibiotic Innovators?
Life will have terrible blows in it, horrible blows, unfair blows. It doesn't matter. And some people recover and others don't. And there I think the . . .
Posted on 7/5/18
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July . . .
Posted on 7/5/18
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant . . .
Posted on 7/5/18
Boston Scientific to Acquire Cryterion Medical
Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Cryterion Medical, Inc., a privately-held company developing
Posted on 7/5/18
KCR Expands its Service Portfolio with Trial Execution Consulting
BOSTON--(BUSINESS WIRE)--KCR, a full-service contract research organization, is extending its service portfolio with Trial Execution Consulting to support clients in translating scientific objectives into operational activity. . . .
Posted on 7/5/18
Berkshire Hathaway: Still Has A Lot Of Room For Appreciation
IntroductionCurrently, Berkshire Hathaway's (NYSE:BRK.A) (NYSE:BRK.B) shares are down almost 14% from their historical high of $217.19 now trading under around $186. Book value for the company . . .
Posted on 7/4/18
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., July 03, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to nine new employees for an . . .
Posted on 7/3/18
Peak Physical Therapy & Sports Performance Sponsors and Provides Stretching Tent for "Run 4 Scituate"
In keeping with a commitment to give back to the local communities it serves, Peak Physical Therapy & Sports Performance, a South Shore practice specializing in . . .
Posted on 7/2/18
BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® Production
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has contracted with the Connell . . .
Posted on 7/2/18
Biogen (BIIB) Building A Stroke Portfolio - Slideshow
The following slide deck was published by Biogen Inc. in conjunction with this event. READ FULL ARTICLE HERE
Posted on 7/2/18
Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
If you like putting money into the beaten-down stocks of clinical-stage biotechs, Ziopharm Oncology (NASDAQ:ZIOP) and Celldex Therapeutics (NASDAQ:CLDX) might warrant a look. Ziopharm's share price . . .
Posted on 7/2/18
Is Cara Therapeutics, Inc. a Buy?
It's been a very good week for Cara Therapeutics, Inc. (NASDAQ:CARA). The biotech stock soared after Cara reported positive results from a phase 2/3 clinical study . . .
Posted on 7/1/18
Major Academic Health System Taps Glytec for Insulin Management Technology
WALTHAM, Mass.--(BUSINESS WIRE)--With national statistics indicating that one of every three hospitalized patients requires insulin therapy during their stay, administering the right dose at the right . . .
Posted on 7/1/18
Arch Therapeutics $4.5 Million Registered Direct Offering
FRAMINGHAM, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH), a developer of innovative materials as hemostatic and wound care devices, today announced the . . .
Posted on 6/28/18
Akebia Therapeutics and Keryx Biopharmaceuticals to Merge
Akebia Therapeutics, Inc. (NASDAQ:AKBA) and Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that the companies signed, and the boards
Posted on 6/28/18
BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding
CAMBRIDGE, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--BioAxone BioSciences, Inc. announced today that, as part of a collaborative effort with RXi Pharmaceuticals Corporation (NASDAQ: RXII), it is the . . .
Posted on 6/28/18
ObserveIT Named Best Place to Work from Boston Business Journal for Second Year in a Row
BOSTON--(BUSINESS WIRE)--ObserveIT, the leading insider threat management provider with more than 1,700 customers around the world, today announced that the Boston Business Journal (BBJ) has named . . .
Posted on 6/28/18
LogPoint and DFLabs Join Forces
COPENHAGEN, BOSTON & MILAN--(BUSINESS WIRE)--LogPoint, the next generation SIEM and Big Data Analytics company, has joined forces with DFLabs, the pioneer in Security Orchestration, Automation and . . .
Posted on 6/28/18
Cara Therapeutics: Scratching An Itch Left Unscratched
Company Introduction And ThesisCara Therapeutics Inc. (CARA) is a small-cap biopharmaceutical company whose focus revolves around pruritus (severe itch) and pain, specifically through selective targeting and . . .
Posted on 6/27/18
Translate Bio Announces Pricing of IPO
LEXINGTON, Mass.--(BUSINESS WIRE)--Translate Bio, Inc. (Nasdaq: TBIO) a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused . . .
Posted on 6/27/18
Zafgen Announces Proposed Offering of Common Stock
BOSTON, June 27, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients . . .

